What are the appropriate prokinetic agents, their dosing regimens, and safety considerations for managing gastroparesis?

Prokinetic Medications for Gastroparesis

For gastroparesis, metoclopramide is the first-line prokinetic agent, starting at 5 mg three times daily before meals and titrating up to 10 mg as needed, with erythromycin (40-150 mg before meals using oral suspension) as an alternative first-line option. 1

First-Line Prokinetic Agents

Metoclopramide (Preferred First-Line)

The 2025 AGA guidelines conditionally suggest using metoclopramide as the primary prokinetic agent 1. This is the only FDA-approved medication specifically for gastroparesis 2.

Dosing regimen:

• Start with 5 mg orally three times daily before meals
• Titrate up to 10 mg three times daily based on response
• Intranasal formulation: 15 mg before meals and at bedtime 1

Critical safety considerations:

• FDA black box warning for tardive dyskinesia risk - discuss this with patients before initiating treatment 1
• Higher risk in patients on psychotropic agents and elderly individuals, though absolute risk remains low 1
• Assess efficacy and adverse effects (including movement disorders) at 4-8 weeks to determine continuation 1
• Consider drug holidays of 1-4 weeks every 8-12 weeks to improve tolerability 1

Erythromycin (Alternative First-Line)

Works through motilin receptor agonism, not antibiotic properties 1.

Dosing regimen:

• Use low doses: 40-150 mg orally 30 minutes before meals
• Use erythromycin ethylsuccinate oral suspension (not tablets) to allow smaller, better-tolerated doses since tablets only come in high doses (250-500 mg) 1

Critical safety considerations:

• Tachyphylaxis develops with continuous use - maintain efficacy with drug holidays (3 weeks on, 1 week off) 1
• QT prolongation risk 1
• CYP3A inhibitor - check for drug interactions 1
• Antibiotic resistance with long-term use 1
• Azithromycin can substitute with similar safety concerns 1

Second-Line Options (NOT First-Line)

Domperidone

The AGA suggests AGAINST domperidone as first-line treatment (conditional recommendation, very low quality evidence) 1.

When to consider:

• Patients who developed neurologic adverse effects with metoclopramide 1
• Patients with Parkinson's disease or other movement disorders 1
• Patients refusing metoclopramide due to safety concerns 1

Major barriers:

• Not FDA-approved in the United States - requires expanded access IND application 1
• Current U.S. supplier exiting the market (as of 2025 guideline publication) 1

If available, safety monitoring required:

• Baseline: serum potassium, magnesium, ECG for QTc interval 1
• Ongoing: monitor electrolytes and QTc while on treatment 1
• Assess efficacy at 4-8 weeks 1

Prucalopride

The AGA suggests AGAINST prucalopride as first-line treatment (conditional recommendation, very low quality evidence) 1.

When to consider:

• Idiopathic gastroparesis (more likely to respond than diabetic or connective tissue disease-related) 1
• Patients with concurrent chronic idiopathic constipation (CIC) - efficiency of treating both conditions 1

Mechanism and monitoring:

• Pure prokinetic via 5HT4 receptor agonism - no antiemetic effect 1
• Monitor for depression and suicidal ideation (small risk) 1

Agents NOT Recommended as First-Line

Nortriptyline

The AGA suggests AGAINST nortriptyline as first-line treatment (conditional recommendation, low quality evidence) 1.

When to consider:

• Overlapping irritable bowel syndrome 1
• Functional dyspepsia with epigastric pain 1
• Significant abdominal pain with gastroparesis 1

Dosing approach:

• Start low, increase slowly to ensure tolerance 1
• Use agents with fewer anticholinergic effects (nortriptyline preferred over amitriptyline) 1
• Explain to patients this is used as peripheral neuromodulator, not for depression 1

Buspirone

The AGA suggests AGAINST buspirone as first-line treatment (conditional recommendation, very low quality evidence) 1.

When to consider:

• Predominant early satiety, postprandial fullness, and bloating 1

Treatment Algorithm

Step 1: Optimize baseline management

• Control glycemia in diabetic patients 1
• Eliminate medications delaying gastric emptying (opiates, GLP-1 agonists) 1
• Implement dietary modifications (small-particle, low-fat, low-residue diet) 1

Step 2: Add antiemetics as needed (not prokinetics)

• 5HT3 antagonists (ondansetron, granisetron) 1, 3
• H1 antagonists (promethazine) 1
• D2 antagonists (prochlorperazine) 1
• These reduce nausea/vomiting without affecting gastric emptying 1

Step 3: Initiate first-line prokinetic

• Metoclopramide 5 mg three times daily before meals OR
• Erythromycin 40-150 mg (suspension) 30 minutes before meals

Step 4: Assess response at 4-8 weeks

• Continue if effective and tolerated 1
• If ineffective or intolerable, consider second-line options based on symptom profile:
  • Predominant nausea/vomiting with metoclopramide intolerance → domperidone (if available) 1
  • Idiopathic gastroparesis with constipation → prucalopride 1
  • Predominant abdominal pain → nortriptyline 1
  • Predominant early satiety/fullness → buspirone 1

Common Pitfalls to Avoid

1. Using high-dose erythromycin tablets - always use oral suspension for proper low-dose administration 1

2. Continuous erythromycin without drug holidays - leads to tachyphylaxis; implement scheduled breaks 1

3. Failing to discuss tardive dyskinesia risk before starting metoclopramide - FDA black box warning requires informed consent 1

4. Ignoring drug interactions with erythromycin - it's a CYP3A inhibitor 1

5. Not monitoring QTc with domperidone or erythromycin - both prolong QT interval 1

6. Expecting antiemetic effects from prucalopride - it's purely prokinetic with no direct antiemetic action 1

7. Using domperidone without proper FDA authorization - requires IND application and may not be available 1